整合基线心脏病、高血压和对数左前降支冠状动脉放疗剂量的肺癌主要不良心脏事件风险预测模型(CHyLL)
本研究基于701例接受根治性放疗的局部晚期非小细胞肺癌患者,开发并验证了整合冠心病、高血压和对数左前降支≥15 Gy体积百分比(LADV15)的主要不良心脏事件(MACE)预测模型CHyLL。模型在测试队列中c-index为0.76,低风险(评分<5.00)与高风险(评分≥5)组48个月MACE发生率分别为6.8%和23.6%(p=0.041),生存率分别为51.6%和35.0%(p=0.099)。
要点
- CHyLL模型纳入冠心病、高血压、对数LADV15及冠心病与对数LADV15交互项,自举法c-index为0.80,测试队列c-index为0.76。
- 测试队列中低风险(评分<5.00)与高风险(评分≥5)组48个月MACE发生率为6.8% vs 23.6%(p=0.041),生存率为51.6% vs 35.0%(p=0.099)。
- 无冠心病患者若合并高血压,为保持低风险,计算出的LADV15约束为11.3%;无高血压者为28.3%。
核心结论
- 既往冠心病、高血压和LADV15是放疗后MACE的重要预测因素,CHyLL有潜力基于心脏危险因素和可接受的MACE阈值来估计个体化LADV15约束。
研究设计与样本
- 总701例接受根治性放疗的局部晚期非小细胞肺癌患者按诊断日期分为开发队列(n=500)和测试队列(n=201)。
- 开发队列采用多变量Cox比例风险模型 backward elimination(Bonferroni校正α=0.025),候选预测因子包括年龄、冠心病、Framingham风险、高血压、平均心脏剂量、LADV15、调强放疗使用及冠心病与LADV15交互项。
- 心脏剂量探索了二次、平方根和对数(ln[X+1])形式,模型通过自举法进行内部验证。
主要发现
- 最终模型CHyLL纳入冠心病、高血压、对数LADV15和冠心病*ln[LADV15+1](β系数:5.51、1.28、1.48、-1.36;所有p<0.025;自举法c-index:0.80;测试队列c-index:0.76)。
- 可能的风险评分范围为0-8.11。
- 测试队列中低风险(评分<5.00)与高风险(评分≥5)组48个月MACE发生率为6.8% vs 23.6%(p=0.041),生存率为51.6% vs 35.0%(p=0.099)。
- 使用该模型计算,无冠心病患者中合并高血压者与未合并高血压者为保持低风险,LADV15约束分别为11.3%和28.3%。
关键数值与推荐
- CHyLL模型β系数:冠心病5.51、高血压1.28、对数LADV15 1.48、冠心病*ln[LADV15+1] -1.36,所有p<0.025。
- 风险评分范围0-8.11,低风险定义为评分<5.00,高风险定义为评分≥5。
- 无冠心病患者中,合并高血压者LADV15约束为11.3%,未合并高血压者为28.3%,以保持低风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In patients with locally advanced non-small cell lung cancer (LA-NSCLC) post-radiotherapy, mean heart dose (MHD) and the percent of left anterior descending (LAD) coronary artery receiving ≥15 Gy (LADV15) are associated with major adverse cardiac events (MACE). We developed a MACE prediction model in this population. MATERIALS AND METHODS: Total 701 patients with LA-NSCLC treated with curative-intent radiotherapy reviewed, split by diagnosis date into "development" (n = 500) and later (n = 201) "test" cohorts. Development patients were analyzed using a multivariable Cox-proportional hazard model with backward elimination scheme (Bonferroni-adjusted α = 0.025). Potential predictors were selected a priori: age, coronary heart disease (CHD), Framingham Risk, hypertension, MHD, LADV15, intensity modulated radiotherapy use, and CHD and LADV15 interaction (CHD:LADV15). Cardiac doses as quadratic, square root, and logarithmic (ln[X + 1]) forms were explored. Models were internally validated with bootstrapping. RESULTS: Final model incorporated CHD, Hypertension, Logarithmic LADV15, and CHD*ln[LADV15 + 1] (CHyLL; β coefficients: 5.51, 1.28, 1.48, -1.36; all p < 0.025; bootstrapping c-index: 0.80; test cohort c-index: 0.76). Possible risk score range: 0-8.11. MACE incidence was 6.8% and 23.6% at 48 months (p = 0.041), and survival rates were 51.6% and 35.0% (p = 0.099), in the low-risk (score <5.00) and high-risk (score ≥5) test groups, respectively. Using the model, calculated LADV15 constraints for patients without CHD were 11.3% and 28.3% for those with and without hypertension, respectively, to remain low-risk. CONCLUSIONS: Pre-existing CHD, hypertension, and LADV15 were important factors in predicting MACE after radiotherapy. CHyLL has the potential to estimate personalized LADV15 constraints based on cardiac risk factors and acceptable MACE thresholds.
引用
- Tjong MC, Bitterman DS, Brantley K, et al. Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL). Radiother Oncol. 2022. PMID: 35182687. doi:10.1016/j.radonc.2022.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。